COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations


1Wroclaw Medical University
2Universidad de Málaga Facultad de Medicina
3Complutense University of Madrid
4University of Zurich
5The Hospital for Sick Children
6Center of Physiology, Pathophysiology and Immunology
7Universidad San Pablo CEU
8University of Wroclaw
9Imperial College London
10Paul-Ehrlich-Institut,
11Paul-Ehrlich-Institut
12Humanitas University Head Personalized Medicine Asthma & Allergy Clinic-Humanitas Research Hospital-IRCCS, Milano, Italy
13Stanford University
14Transylvania University of Brasov
15University of Zürich
16NRC Institute of Immunology
17Hospital General Universitario Gregorio Marañón
18Hospital Sant Joan de Deu
19University of Belgrade, Faculty of Medicine
20Bispebjerg University Hospital
21Sorbonne Universités, UPMC Univ Paris 06
22Ankara University Faculty of Medicine
23University Hospital Strasbourg
24Imperial College London Faculty of Medicine
25National Research Council
26Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
27Technical University of Munich
28University of Rome Tor Vergata
29National University of Athens, Medical School
30Univ CEU San Pablo
31the children's Hospital of Philadelphia
32University of California, Los Angeles
33Univ Hosp Geneva
34University College Cork (UCC)
35Sagamihara National Hospital
36University of Cagliari
37Medical University of Silesia
38Istanbul University
39Odense University Hospital
40European Academy of Allergy and Clinical Immunology; Department of Clinical Medicine, Aarhus University
41Medical University Vienna
42Center for Rhinology and Allergology Wiesbaden
43University of Helsinki
44Hospital Universitario Lucus Augusti
45Azienda Ospedaliero-Universitaria Careggi
46Imperial College
47Faculty of Medicine
48National Research Institute for Child Health and Development
49Massachusetts General Hospital and Harvard Medical School
50University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
51Universitatea de Medicina si Farmacie Carol Davila
52Fundación Jiménez Díaz
53University of Leeds
54Academic Medical Center
55Hospital Clinico San Carlos
56Allergy Unit Complesso Integrato Columbus, Rome and IRCCS Oasi Maria S.S., Troina, Italy
57King's College London Faculty of Life Sciences and Medicine
58Motol University Hospital Department of Cardiology 2nd Faculty of Medicine
59Royal Brompton & Harefield
60Uniwersytet Medyczny im Piastow Slaskich we Wroclawiu
Abstract

Immune modulation is a key therapeutic tool for allergic diseases and asthma. It can be achieved in an antigen-specific way via allergen immunotherapy (AIT) or in endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: IgE, IL-5 and IL-4/IL-13. COVID-19 vaccine provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. It works as well through immune modulation. Thus, as there is an obvious interference between these treatment modalities recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) gathered an outstanding expert panel under its Research and Outreach Committee (ROC). This expert panel was called to evaluate the evidence and formulate recommendation on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.

Hosted file